Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
I tiakina i:
| Ngā kaituhi matua: | , |
|---|---|
| Hōputu: | Revisão |
| Reo: | Ingarihi |
| I whakaputaina: |
2014
|
| Urunga tuihono: | https://doi.org/10.1517/14728222.2014.960843 |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|